Download full-text PDF |
Source |
---|
Front Immunol
January 2025
Department of Dermatology, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Biological drugs are extensively used to treat various inflammatory diseases, including psoriasis, atopic dermatitis (AD), and rheumatoid arthritis. While generally effective and safe, these therapies have been increasingly associated with secondary development of vitiligo, especially with anti-TNF α and anti-IL17 drugs. Dupilumab, an IL-4 receptor alpha antagonist used in moderate to severe AD, rarely induces vitiligo.
View Article and Find Full Text PDFItal J Dermatol Venerol
November 2024
Department of Dermatology, 'Maggiore' Hospital, University of Trieste, Trieste, Italy.
Arch Dermatol Res
June 2024
Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.
A knowledge gap exists regarding the association between vitiligo and rheumatoid arthritis (RA) due to the absence of large-scale cohort studies designed to investigate this association. To investigate the bidirectional epidemiological association between vitiligo and RA. A population-based study was conducted using Clalit Health Services (CHS) database (2002-2019) using both a cohort study and a case-control study design.
View Article and Find Full Text PDFFront Neurol
May 2024
Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.
Objective: Our knowledge about the association between vitiligo and Parkinson's disease (PD) is sparse. We sought to investigate the bidirectional epidemiological association between vitiligo and PD.
Methods: A population-based study was conducted using Clalit Health Services (CHS) database (2002-2019) using both a cohort study and a case-control study design.
Arch Dermatol Res
March 2024
Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!